Monopar Therapeutics - Significant Ownership

Signature - Title
Karl Leo - Managing Member
Location
Wilmette, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Monopar Therapeutics.

Notify me when Monopar Therapeutics files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Monopar Therapeutics

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MNPR Gem Pharmaceuticals LLC Common Stock, $0.001 par value 13.4% $24.6M 705K Hendricks Diane Dec 9, 2024

Schedules 13D/G Reported by Monopar Therapeutics:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.